QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets. The company also offers ingenuity variant analysis, a cloud-based platform to evaluate data generated by NGS technologies; CLC cancer research workbench, a cancer-focused informatics solution; and GeneGlobe, a Web-based portal that enables researchers to search and select from pre-designed and custom PCR assay kits and NGS assay panels. In addition, it provides co-development, technology licenses and patent sales, and custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production. Further, the company offers instrumentation systems for laboratories to perform nucleic acid sample preparation, assay setup, target detection, and interpretation of genomic information. Its automation platforms include QIAsymphony, a modular system; EZ1 Advanced XL for automated nucleic acid purification; QIAcube, a sample processing instrument; QIAcube HT for automated nucleic acid purification; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAgility, a compact benchtop instrument; QIAxcel for nucleic acid separation; and ESEQuant Tube Scanners. The company serves molecular diagnostics, applied testing, pharma, and academia customers. It has collaboration agreement with Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Exosome Diagnostics Inc., 10x Genomics, and Novartis AG. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.